Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune multi-systemic disorder of the connective tissue, characterized mainly by involvement of the skin, joints, kidneys, and serosal membranes. It affects females particularly at childbearing age more commonly than males. Lupus nephritis affects around half of patients with SLE. Data about SLE and lupus nephritis in Saudi Arabia are still scarce. In this study, we aimed to evaluate the prevalence, clinical and laboratory findings of SLE and different histological types of lupus nephritis among Saudi patients at King Fahad Medical City. Methods This is a retrospective study for adult patients who have been evaluated at king Fahad medical city between 2014 and 2019 and fulfilled the Systemic Lupus International Collaborating Clinics classification criteria (SLICC). Results 112 patients, 103 (92%) females and 9 (8%) males, with confirmed diagnoses of SLE were reviewed. Skin rash (69.6%), photosensitivity (61.6%), mucosal ulcerations (45.9%), arthralgia and/or arthritis (44.6%) are the most common clinical features. Ninety seven (86.6%) out of 112 patients had a recorded first visit 24 hour urine protein level, out of those only 26 (23.2) patients presented with significant proteinuria of more than 0.5grams per day. Forty four (39.2%) have undergone kidney biopsy. Class IV and III lupus nephritis are the most common reported biopsy results (43.18% and 27.28% respectively). During the study period, three patients (2.7%) developed end-stage kidney disease requiring dialysis and five (4.5%) had renal transplant. Conclusion Our study provided insight on the demographics, characteristics and presentation of SLE patients and the outcome of lupus nephritis in Saudi Arabia.
Background:Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play a major role in the development of LN and anti-Ro antibodies have also been implicated. McCarty et al suggested that women of African ancestry with the unusual autoantibody combination of anti-Sm, Ro & RNP antibodies (AB) were at increased risk of developing LN (1).Objectives:Our aim was to determine the correlation between autoantibody profile: Sm, Ro and RNP as a combination in the development of LN in patients with African ancestry. We investigated time to the development of LN from SLE onset.Methods:A retrospective case-control study was conducted at Guys and St Thomas NHS Trust, London, United Kingdom.75 patients with confirmed LN meeting the ACR classification criteria for SLE and Nephritis, were included: African (n=35), Caucasian (n=22) and Asian (n=17) ancestry. LN patients with the combination of Sm, Ro and RNP antibodies (Group 1) were compared to LN patients without this autoantibody combination (Group 2). Demographic data, pathology results and laboratory findings were collected.Anonymised data was analyzed using Statistical Package for Social Sciences (SPSS). Left censorship bias was reduced by use of a database of confirmed LN in our cohort of patients. Research and Development Office approval was obtained for this study.Results:There were 66 (88%) females and 9 (12%) males. The median age in Group 1 was 39 years (range 18-60), while in group 2 the median age was 45 years (range 24-64).We stratified our population based on their antibody status: Of the 75 (100%) patients, 32 (42.6%) patients had the combination of Sm, Ro & RNP antibodies (Group 1) while the remaining 43 (57.4%) patients did not (Group 2).In Group 1, regardless of ethnicity, 29 (90.6%) patients developed LN within 5 years or less from the onset of SLE symptoms, while the remaining 3 (9.4%) developed LN after 5 years. In contrast, in Group 2, 24 (55.8%) patients developed LN within 5 years or less while 19 (44.2%) developed LN after 5 years. (P value = 0.002)Further stratification was based on ethnicity and antibody (AB) status to investigate the time to develop LN from SLE symptom onset: African ancestry with positive AB, African with negative AB, Asian with positive AB, Caucasian with positive AB and Asian & Caucasian with negative Ab. Analysis showed that of 29 (38.7%) African ethnicity patients with the autoantibody combination, 19 (65.5%), developed LN within 5 years. In comparison, 46 (61.3%) patients, independent of ethnicity and AB status, developed LN after 5 years (P value = 0.01).Conclusion:Patients with the unusual autoantibody combination of Sm, Ro & RNP developed LN significantly earlier than patients who did not have this combination. This autoantibody combination was significantly over represented in the African ancestry patients. Our data suggests that African ancestry patients with this autoantibody combination are at increased risk of developing LN soon after SLE symptom onset and merit close monitoring for the development of renal disease.References:[1]McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in Black female patients with lupus nephritis. Arthritis & Rheumatism. 1993; 36:1560-1565Table 1.1Ethnicity with Autoantibody status showing the rate of progression into Lupus Nephritis.Duration of LN onsetTotalLess than 5 years after SLE onsetMore than 5 years after SLE onsetEthnicity with AB statusAfrican with positive19322African with negative9413Asian with positive505Caucasian with positive505Other negatives151530Total532275Graph 1.Ethnicity with Autoantibody status showing the rate of progression into Lupus Nephritis (P value= 0.01)Disclosure of Interests:Majed Albirdisi: None declared, David d’cruz Grant/research support from: GlaxoSmithKline, Shirish Sangle: None declared, Natasha Jordan: None declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.